Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 first in human study assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117567 in healthy adult participants

Next Previous
Trial Profile

A phase 1 first in human study assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117567 in healthy adult participants

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NBI-1117567 (Primary)
  • Indications Neurological disorders
  • Focus Adverse reactions; First in man

Most Recent Events

  • 14 Jan 2025 According to a Nxera Pharma Co., Ltd. media release, the company anticipates receiving data readouts in 2025.
  • 08 May 2024 Status changed from planning to recruiting as per Neurocrine Biosciences media release
  • 16 Apr 2024 According to a Nxera Pharma Co., Ltd. media release, the company expected to enter Phase 1 in 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top